Hypertensive emergencies, characterized by severe elevations in blood pressure (BP) with end-organ damage, present a significant challenge in clinical practice. Early identification and appropriate management is critical to prevent irreversible organ damage and reduce morbidity and mortality.
Patients with hypertensive emergencies often present with severe hypertension (systolic BP >180 mmHg or diastolic BP >120 mmHg). The key to identification is the recognition of end-organ damage, which may manifest as neurological, cardiovascular, renal, or retinal complications. Detailed clinical assessment and relevant investigations are essential to confirm the diagnosis.
Initial management of hypertensive emergencies involves stabilization of the patient and reduction of BP. This should be done cautiously to avoid rapid reduction in BP, which may lead to end-organ hypoperfusion. Parenteral antihypertensive medications are often required for immediate BP control. The choice of medication depends on the specific organ system involved.
Recent advances in the treatment of hypertensive emergencies include the use of novel antihypertensive agents and targeted therapies. Sodium nitroprusside, once a mainstay of treatment, is being replaced by agents such as clevidipine and fenoldopam due to their better safety profiles. There is also growing interest in the use of renal denervation and baroreceptor activation therapy for resistant hypertension.
Hypertensive emergencies require prompt identification and effective management to prevent serious complications. While traditional antihypertensive medications remain the cornerstone of treatment, novel therapies offer promising alternatives. Continued research and clinical trials are essential to further improve our understanding and management of this complex condition.
1.
New Nanoparticles Can Destroy Undruggable Cancer Proteins
2.
Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer
3.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
4.
Belzutifan Plus Pembro Approved for Adjuvant RCC
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
2.
Obesity as a major risk factor for cancer
3.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
4.
Advanced Pathways in Oncology for Better Care
5.
Essential Updates in Hematology in Daily Practice
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Understanding Anemia and Its Common Causes
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Early Cancer Detection Saves Lives
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation